+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Asia Pacific Multiple Sclerosis Therapeutics Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Drug Class, Route of Administration, and Distribution Channel

  • ID: 5359921
  • Report
  • May 2021
  • Region: Asia Pacific
  • 138 pages
  • The Insight Partners
UP TO OFF
until Sep 30th 2021

FEATURED COMPANIES

  • Bayer AG
  • Biogen
  • F. HOFFMANN-LA ROCHE LTD
  • Merck & Co., Inc.
  • Novartis AG
  • Sanofi
  • MORE
The immunosuppressants segment by drug class is estimated to lead the market growth during the forecast period.



According to this study, the Asia Pacific multiple sclerosis therapeutics market is expected to reach US$ 7,130.85 million by 2027 from US$ 4,129.20 million in 2019; it is estimated to grow with a CAGR of 7.2% from 2020 to 2027. The report highlights trends prevailing in the Asia Pacific multiple sclerosis therapeutics market and the factors driving market along with those that act as hindrances.

The Asia Pacific multiple sclerosis therapeutics market, by drug class, is segmented into immunosuppressant and immunomodulators. The immunomodulators segment held the largest share of the market in 2019, whereas the immunosuppressants segment is anticipated to register the highest CAGR in the market during the forecast period.

Multiple sclerosis is a widespread disabling neurological condition that is mostly diagnosed in people in the age group of 20-50 years. The market is witnessing significant investments in clinical research and developments. Many pharmaceutical companies are focusing on developing novel therapies for the treatment of MS. Increased research have also paved the way for many research collaborations between pharmaceutical companies and research institutes. Increased research on various novel candidates has resulted in strengthening the pipeline portfolio of leading and small-scale pharmaceutical companies. The expected launch of these pipeline candidates drives the growth of the Asia Pacific multiple sclerosis treatment market. Also, the rising prevalence of the disease has forced governments of many countries to take proactive measures through guidelines and recommendations. Various awareness initiatives are also being launched by government associations to educate patients regarding MS drugs and treatments options available in the market, which boost the market growth.

Asia Pacific countries are witnessing massive challenges due to the increasing number of COVID-19 confirmed cases. The COVID-19 outbreak has severely affected the healthcare industry, considering the economic conditions in the current situation. Precautionary measures have been taken to control the spread of the novel coronavirus. However, in this measure, hospitals, clinics, diagnostic centers, and ambulatory surgery centers (ASCs) are not attending any general patient on priority. Universities across Asia Pacific are closed. Also, access to research labs is restricted, ongoing projects are postponed, fieldwork is interrupted, and travelling is prohibited. All these factors are restraining the growth of the Asia Pacific multiple sclerosis therapeutics market.

The growth of the market is attributed to some key driving factors such as increasing prevalence of multiple sclerosis and rise in funding for multiple sclerosis research. However, the high cost of the multiple sclerosis treatment may hinder the market growth.

Merck & Co., Inc., Novartis AG, Bayer AG, Sanofi, Bristol-Myers Squibb Company, TEVA PHARMACEUTICAL INDUSTRIES LTD, Takeda Pharmaceutical Company Limited, F. HOFFMANN-LA ROCHE LTD, and Biogen are among the leading companies operating in Asia Pacific multiple sclerosis therapeutics market.

The report segments in Asia Pacific Multiple Sclerosis Therapeutics Market as follows:

By Drug Class
  • Immunosuppressant
  • Immunomodulators
By Route of Administration
  • Injectable
  • Oral
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • E-Commerce
By Country
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Bayer AG
  • Biogen
  • F. HOFFMANN-LA ROCHE LTD
  • Merck & Co., Inc.
  • Novartis AG
  • Sanofi
  • MORE
1. Introduction
1.1 Scope of the Study
1.2 The Publisher's Research Report Guidance
1.3 Market Segmentation
1.3.1 Asia Pacific Multiple Sclerosis Therapeutics Market - By Drug Class
1.3.2 Asia Pacific Multiple Sclerosis Therapeutics Market - By Route of Administration
1.3.3 Asia Pacific Multiple Sclerosis Therapeutics Market - By Distribution Channel
1.3.4 Asia Pacific Multiple Sclerosis Therapeutics Market - By Country

2. Multiple Sclerosis Therapeutics Market - Key Takeaways

3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Asia Pacific Multiple Sclerosis Therapeutics- Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 Asia Pacific - PEST Analysis
4.3 Expert Opinions

5. Multiple Sclerosis Therapeutics Market - Key Market Dynamics
5.1 Market Drivers
5.1.1 Growing Prevalence of Multiple Sclerosis (MS)
5.1.2 Rising Funding for Multiple Sclerosis Research
5.2 Market Restraints
5.2.1 High Cost of Multiple Sclerosis Treatment
5.3 Market Opportunities
5.3.1 Increasing Awareness About Multiple Sclerosis
5.4 Future Trends
5.4.1 Development and Launch of Innovative Products
5.5 Impact analysis

6. Multiple Sclerosis Therapeutics Market - Asia Pacific Analysis
6.1 Asia Pacific Multiple Sclerosis Therapeutics Market Revenue Forecast and Analysis

7. Multiple Sclerosis Therapeutics Market Analysis - By Drug Class
7.1 Overview
7.2 Multiple Sclerosis Therapeutics Market Revenue Share, by Drug Class (2019 and 2027)
7.3 Immunosuppressant
7.3.1 Overview
7.3.2 Immunosuppressant: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)
7.4 Immunomodulators
7.4.1 Overview
7.4.2 Immunomodulators: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)

8. Multiple Sclerosis Therapeutics Market Analysis - By Route of Administration
8.1 Overview
8.2 Multiple Sclerosis Therapeutics Market Revenue Share, by Route of Administration (2019 and 2027)
8.3 Injectable
8.3.1 Overview
8.3.2 Injectable: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)
8.4 Oral
8.4.1 Overview
8.4.2 Oral: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)

9. Multiple Sclerosis Therapeutics Market Analysis - By Distribution Channel
9.1 Overview
9.2 Multiple Sclerosis Therapeutics Market Share, by Distribution Channel, 2019 and 2027
9.3 Hospital Pharmacies
9.3.1 Overview
9.3.2 Hospital Pharmacies: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)
9.4 Retail Pharmacies
9.4.1 Overview
9.4.2 Retail Pharmacies: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)
9.5 E-Commerce
9.5.1 Overview
9.5.2 E-Commerce: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)

10. Multiple Sclerosis Therapeutics Market Analysis and Forecast To 2027 - Asia Pacific Analysis
10.1 Asia Pacific Multiple Sclerosis Therapeutics Market Revenue and Forecasts To 2027
10.1.1 Overview
10.1.2 Asia Pacific Multiple Sclerosis Therapeutics Market share, By Country (2019 & 2027) (%)
10.1.3 China Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027 (US$ Mn)
10.1.3.1 China Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027 (US$ Mn)
10.1.3.2 China Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027, By Drug Class (US$ Mn)
10.1.3.3 China Multiple Sclerosis Therapeutics Market Revenue and Forecasts To 2027, By Route of Administration (US$ Mn)
10.1.3.4 China Multiple Sclerosis Therapeutics Market Revenue and Forecasts To 2027, By Distribution Channel (US$ Mn)
10.1.4 Japan Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027 (US$ Mn)
10.1.4.1 Japan Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027 (US$ Mn)
10.1.4.2 Japan Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027, By Drug Class (US$ Mn)
10.1.4.3 Japan Multiple Sclerosis Therapeutics Market Revenue and Forecasts To 2027, By Route of Administration (US$ Mn)
10.1.4.4 Japan Multiple Sclerosis Therapeutics Market Revenue and Forecasts To 2027, By Distribution Channel (US$ Mn)
10.1.5 India Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027 (US$ Mn)
10.1.5.1 India Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027 (US$ Mn)
10.1.5.2 India Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027, By Drug Class (US$ Mn)
10.1.5.3 India Multiple Sclerosis Therapeutics Market Revenue and Forecasts To 2027, By Route of Administration (US$ Mn)
10.1.5.4 India Multiple Sclerosis Therapeutics Market Revenue and Forecasts To 2027, By Distribution Channel (US$ Mn)
10.1.6 South Korea Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027 (US$ Mn)
10.1.6.1 South Korea Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027 (US$ Mn)
10.1.6.2 South Korea Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027, By Drug Class (US$ Mn)
10.1.6.3 South Korea Multiple Sclerosis Therapeutics Market Revenue and Forecasts To 2027, By Distribution Channel (US$ Mn)
10.1.6.4 South Korea Multiple Sclerosis Therapeutics Market Revenue and Forecasts To 2027, By Distribution Channel (US$ Mn)
10.1.7 Australia Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027 (US$ Mn)
10.1.7.1 Australia Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027 (US$ Mn)
10.1.7.2 Australia Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027, By Drug Class (US$ Mn)
10.1.7.3 Australia Multiple Sclerosis Therapeutics Market Revenue and Forecasts To 2027, By Route of Administration (US$ Mn)
10.1.7.4 Australia Multiple Sclerosis Therapeutics Market Revenue and Forecasts To 2027, By Distribution Channel (US$ Mn)
10.1.8 Rest of Asia Pacific: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)

11. Impact of COVID-19 Pandemic on Asia Pacific Multiple Sclerosis Therapeutics Market
11.1 Asia-Pacific: Impact Assessment of COVID-19 Pandemic

12. Industry Landscape
12.1 Overview
12.2 Organic Developments
12.2.1 Overview
12.3 Inorganic Developments
12.3.1 Overview

13. Company Profiles
13.1 Merck & Co., Inc.
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Novartis AG
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Bayer AG
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Sanofi
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Bristol-Myers Squibb Company
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 TEVA PHARMACEUTICAL INDUSTRIES LTD
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 Takeda Pharmaceutical Company Limited
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 F. HOFFMANN-LA ROCHE LTD.
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 Biogen
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments

14. Appendix
14.1 About the Publisher
14.2 Glossary of Terms

List of Tables
Table 1. China Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027, By Drug Class (US$ Mn)
Table 2. China Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027, By Route of Administration (US$ Mn)
Table 3. China Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027, By Distribution Channel (US$ Mn)
Table 4. Japan Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027, By Drug Class (US$ Mn)
Table 5. Japan Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027, By Route of Administration (US$ Mn)
Table 6. Japan Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027, By Distribution Channel (US$ Mn)
Table 7. India Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027, By Drug Class (US$ Mn)
Table 8. India Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027, By Route of Administration (US$ Mn)
Table 9. India Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027, By Distribution Channel (US$ Mn)
Table 10. South Korea Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027, By Drug Class (US$ Mn)
Table 11. South Korea Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027, By Distribution Channel (US$ Mn)
Table 12. South Korea Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027, By Distribution Channel (US$ Mn)
Table 13. Australia Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027, By Drug Class (US$ Mn)
Table 14. Australia Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027, By Route of Administration (US$ Mn)
Table 15. Australia Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027, By Distribution Channel (US$ Mn)
Table 19. Organic Developments Done By Companies
Table 20. Inorganic Developments Done By Companies
Table 21. Glossary of Terms, Multiple sclerosis therapeutics Market

List of Figures
Figure 1. Multiple Sclerosis Therapeutics Market Segmentation
Figure 2. Multiple Sclerosis Therapeutics Market Segmentation, By Country
Figure 3. Multiple Sclerosis Therapeutics Market Overview
Figure 4. Immunomodulators Segment by Drug Class Held the Larger Share of Asia Pacific Multiple Sclerosis Therapeutics Market
Figure 5. Asia Pacific Multiple Sclerosis Therapeutics Market - Leading Country Markets (US$ Million)
Figure 6. Asia Pacific PEST Analysis
Figure 7. Multiple Sclerosis Therapeutics Market Impact Analysis of Driver and Restraints
Figure 8. Asia Pacific Multiple Sclerosis Therapeutics Market - Revenue Forecast and Analysis - 2019- 2027
Figure 9. Multiple Sclerosis Therapeutics Market Revenue Share, by Drug Class (2019 and 2027)
Figure 10. Immunosuppressant: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)
Figure 11. Immunomodulators: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)
Figure 12. Multiple Sclerosis Therapeutics Market Revenue Share, by Route of Administration (2019 and 2027)
Figure 13. Injectable: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)
Figure 14. Oral: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)
Figure 15. Multiple Sclerosis Therapeutics Market Share, by Distribution Channel, 2019 and 2027
Figure 16. Hospital Pharmacies: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)
Figure 17. Retail Pharmacies: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)
Figure 18. E-Commerce: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)
Figure 19. Asia Pacific Multiple Sclerosis Therapeutics Market Overview, by Country (2019)
Figure 20. Asia Pacific Multiple Sclerosis Therapeutics Market share, By Country (2019 & 2027) (%)
Figure 21. China Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 22. Japan Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 23. India Multiple Sclerosis Therapeutic Market Revenue And Forecasts to 2027 (US$ Mn)
Figure 24. South Korea Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 25. Australia Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 27. Impact of COVID-19 Pandemic in Asia Pacific Country Markets
Note: Product cover images may vary from those shown
  • Merck & Co., Inc.
  • Novartis AG
  • Bayer AG
  • Sanofi
  • Bristol-Myers Squibb Company
  • TEVA PHARMACEUTICAL INDUSTRIES LTD
  • Takeda Pharmaceutical Company Limited
  • F. HOFFMANN-LA ROCHE LTD
  • Biogen
Note: Product cover images may vary from those shown
Adroll
adroll